Adnovate Clinical Data Privacy Policy

The traditional 3+3 dose escalation design has dominated Phase I oncology trials for over two decades (Le Tourneau et al., 2009, Kurzrock, 2021). Three patients per cohort, fixed escalation increments,...

The field of inflammation and immunology has historically revolved around monotherapy—single cytokine blockade or single pathway inhibition. IL-23 inhibitors, TNF-alpha antagonists, and IL-6 receptor blockers: each represent a single point...